Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Joanna Vermeij, Per Karlsson et al.|The Lancet Oncology|2017

Cited by 122